US Food and Drug Administration Review Time of Supplemental New Indication Approvals of Drugs and Biologics, 2017 to 2019

This cross-sectional study examines US Food and Drug Administration regulatory review time of supplemental new indication approvals of drugs and biologics between 2017 and 2019.

Detalles Bibliográficos
Autores principales: Dhodapkar, Meera M., Ross, Joseph S., Ramachandran, Reshma
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Medical Association 2023
Materias:
Research Letter
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10293905/
https://www.ncbi.nlm.nih.gov/pubmed/37358857
http://dx.doi.org/10.1001/jamanetworkopen.2023.18889

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10293905/
https://www.ncbi.nlm.nih.gov/pubmed/37358857
http://dx.doi.org/10.1001/jamanetworkopen.2023.18889

Ejemplares similares